News of Note—U.K. research hub, Bavarian Nordic and more

newspaper
In this week's news of note, Bavarian Nordic named a new CFO. (Pixabay)

Here is some other vaccine news of note for the week.

> Officials in the U.K. outlined a plan for a vaccine research hub to help prevent and respond to outbreaks more effectively. Release

> Bavarian Nordic appointed Henrik Juuel, who has served at Novo Nordisk and Virgin Mobile, as its new CFO. Release

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> In an animal study, National Institute of Allergy and Infectious Diseases researchers reported that an HIV vaccine targeting a vulnerable site on the virus elicited antibodies against dozens of strains from around the world. Release

Read more on
outbreaks Bavarian Nordic NIAID United Kingdom

Suggested Articles

ebola
Vaccines

J&J deploys 200K Ebola vaccine doses to fortify Rwanda's border

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

by Kyle Blankenship
Merck
Vaccines

Gavi authorizes $178M to build Ebola vaccine stockpile

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

by Eric Sagonowsky
shingrix
Vaccines

GSK's Shingrix supply will leap up, CEO says—in 2024, that is

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

by Eric Sagonowsky